---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-082783"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T09:53:32.564493+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared

## Summary
- 66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
- No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).
- Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.
- HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.
- Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026.

## SEC filing metadata
- accession: 0001104659-25-082783
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/0001104659-25-082783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/tm2524197d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-082783
- JSON: https://secwatch.observer/filing/0001104659-25-082783.json
- Plain text: https://secwatch.observer/filing/0001104659-25-082783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.